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Three phase 2b, double-blind, placebo-controlled, randomized efficacy trials have tested
recombinant Adenovirus serotype-5 (rAd5)-vector preventive HIV-1 vaccines: MRKAd5
HIV-1 gag/pol/nef in Step and Phambili, and DNA/rAd5 HIV-1 env/gag/pol in HVTN505.
Due to efficacy futility observed at the first interim analysis in Step and HVTN505, partici-
pants of all three studies were unblinded to their vaccination assignments during the study
but continued follow–up. Rigorous meta-analysis can provide crucial information to advise
the future utility of rAd5-vector vaccines.
Methods
We included participant-level data from all three efficacy trials, and three Phase 1–2 trials
evaluating the HVTN505 vaccine regimen. We predefined two co-primary analysis cohorts
for assessing the vaccine effect on HIV-1 acquisition. The modified-intention-to-treat (MITT)
cohort included all randomly assigned participants HIV-1 uninfected at study entry, who
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received at least the first vaccine/placebo, and the Ad5 cohort included MITT participants
who received at least one dose of rAd5-HIV vaccine or rAd5-placebo. Multivariable Cox
regression models were used to estimate hazard ratios (HRs) of HIV-1 infection (vaccine
vs. placebo) and evaluate HR variation across vaccine regimens, time since vaccination,
and subgroups using interaction tests.
Findings
Results are similar for the MITT and Ad5 cohorts; we summarize MITT cohort results.
Pooled across the efficacy trials, over all follow-up time 403 (n = 224 vaccine; n = 179 pla-
cebo) of 6266 MITT participants acquired HIV-1, with a non-significantly higher incidence in
vaccine recipients (HR 1.21, 95% CI 0.99–1.48, P = 0.06). The HRs significantly differed by
vaccine regimen (interaction P = 0.03; MRKAd5 HR 1.41, 95% CI 1.11–1.78, P = 0.005 vs.
DNA/rAd5 HR 0.88, 95% CI 0.61–1.26, P = 0.48). Results were similar when including the
Phase 1–2 trials. Exploratory analyses based on the efficacy trials supported that the
MRKAd5 vaccine-increased risk was concentrated in Ad5-positive or uncircumcised men
early in follow-up, and in Ad5-negative or circumcised men later. Overall, MRKAd5 vaccine-
increased risk was evident across subgroups except in circumcised Ad5-negative men (HR
0.97, 95% CI 0.58−1.63, P = 0.91); there was little evidence that the DNA/rAd5 vaccine, that
was tested in this subgroup, increased risk (HR 0.88, 95% CI 0.61–1.26, P = 0.48). When
restricting the analysis of Step and Phambili to follow-up time before unblinding, 114 (n = 65
vaccine; n = 49 placebo) of 3770 MITT participants acquired HIV-1, with a non-significantly
higher incidence in MRKAd5 vaccine recipients (HR 1.30, 95% CI 0.89–1.14, P = 0.18).
Interpretation and Significance
The data support increased risk of HIV-1 infection by MRKAd5 over all follow-up time, but
do not support increased risk of HIV-1 infection by DNA/rAd5. This study provides a ratio-
nale for including monitoring plans enabling detection of increased susceptibility to infection
in HIV-1 at-risk populations.
Introduction
Credited to their immunological and manufacturing properties, replication-defective adenovi-
rus (Ad) vectors have been one of the most explored delivery vehicles of vaccines for cancer
and a variety of pathogens, including HIV-1, Plasmodium falciparum,Mycobacterium tubercu-
losis, hepatitis C, Ebola and Influenza (reviewed in [1]). In preventive HIV-1 vaccine develop-
ment, three phase 2b, double-blind, placebo-controlled, randomized efficacy trials have been
conducted to evaluate regimens containing recombinant Ad serotype 5 (rAd5) vector vaccines
expressing HIV-1 antigens. The first two studies, Step [2] and Phambili [3], tested the
MRKAd5 HIV-1 gag/pol/nef vaccine. Vaccinations in Step were stopped early due to efficacy
futility observed at the first interim analysis, which caused the discontinuation of enrollment
and vaccinations in Phambili. The third study, HVTN 505 (HVTN505) [4], tested a DNA
prime- rAd5 HIV-1 env/gag/pol boost vaccine. Vaccinations in HVTN505 were also stopped
early due to efficacy futility observed at the first interim analysis. Shortly after stopping of the
vaccinations, participants of these studies were unblinded to their vaccination assignments but
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continued follow–up (Fig 1). Before the efficacy trials, three Phase 1–2 Triad studies, IAVI
V001 (IAVI001) [5], RV 172 (RV172) [6] and HVTN 204 (HVTN204) [7], tested the same
HVTN505 DNA/rAd5 vaccine regimen.
Post-hoc analysis of Step data revealed trends toward an increased risk of HIV-1 acquisition
among vaccine recipients that waned over time, especially among males who had positive anti-
Ad5 neutralizing antibodies (Ad5-positive) or were uncircumcised at baseline [2, 8]. Such a
finding was not observed in the analyses of Phambili data shortly following study unblinding
[3], nor of the long-term follow-up data [9].To clearly understand whether vaccine-associated
increase of HIV-1 acquisition has occurred in one or more studies, we conducted a meta-analy-
sis using up-to-date participant-level data from the efficacy trials and the three Triad studies.
The objectives were to evaluate: 1) the effect of rAd5 vector vaccines on HIV-1 acquisition, and
2) variation in the effect across vaccine regimens, time since vaccination, and subgroups.
By combining information from multiple studies of similar interventions, a meta-analysis
can provide clearer signals overall and in subgroups. However, this strength is predicated on
the assumption that it is meaningful to combine data from multiple studies conducted in differ-
ent populations with different Ad5 vector characteristics, expressing different HIV-1 antigens,
and employing different vaccine regimens. In this individual participant data (IPD) meta-anal-
ysis, we obtained the raw individual level data from each study before they were combined for
analyses, which is commonly referred to as individual patient data (IPD) meta-analysis when
Fig 1. Enrollment and Follow-up in Step, Phambili and HVTN505. Indicated are dates of unblinding when data were frozen for pre-unblinding analyses,
and the percent of person-years (% pyrs) occurring during the blinded period. HVTN505 is still in active follow-up; HVTN505 data included in the meta-
analysis are as of July 9, 2014.
doi:10.1371/journal.pone.0136626.g001
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diseased study populations are involved. Compared to meta-analysis based on aggregated
study-level summary data, IPD-based meta-analyses is usually more time-consuming but pos-
sesses many advantages, including but not limited to: 1) the statistical analysis can be standard-
ized across studies; 2) complex relationships such as time-dependent effects can be modeled; 3)
prognostic models (e.g., risk scores) can be generated and validated, and multiple individual
level factors can be examined in combination; 4) estimates adjusted for baseline (prognostic)
factors can be produced, which may increase statistical power and allow adjustment for poten-
tial confounding factors; and 5) meta-analysis results for specific subgroups of participants can
be obtained across studies, and differential (treatment) effects can be assessed across individu-
als, which can help reduce between-study heterogeneity (e.g., [10, 11]).
Methods
Study selection and data extraction
Fred Hutchinson Cancer Research Center Institutional Review Board approved the described
study. Consultation with HIV-1 vaccine developers and vaccine research experts, as well as a
systematic literature search through February 2015 of the US National Library of Medicine
(PubMed.gov), Ovid Medline (R) (1946-present) and clinicaltrials.gov was conducted to iden-
tify all randomized trials of Ad5-vectored preventive HIV-1 vaccines (Methods in S1 Support-
ing Information). Participant-level data were directly provided by the coordinating centers of
the selected studies. A completed PRISMA (Preferred Reporting Items for Systematic Reviews
and Meta-Analyses) checklist is provided in S2 Supporting Information.
Individual-study features
The three Phase 2b trials enrolled participants at increased risk for HIV-1 infection in the
Americas and Australia (Step), South Africa (Phambili) and the US (HVTN505); the three
Phase 1–2 trials enrolled participants at low to intermediate risk for HIV-1 infection in East
Africa (IAVI001 and RV172), and in the Americas and South Africa (HVTN204). With the
exception of HVTN505, which enrolled circumcised men who have sex with men (MSM) and
transgender women with no pre-existing anti-Ad5 antibodies (Ad5-negative), the studies
enrolled men and non-pregnant women with no specific eligibility criteria based on baseline
Ad5 serostatus or circumcision status (Table 1). Step and Phambili evaluated the MRKAd5
HIV-1 vaccine administered at weeks 0, 4 and 26 [2, 3]. HVTN505 and the Triad studies evalu-
ated the 6-plasmid VRC-DNA vaccine administered at weeks 0, 4, and 8, followed by the VRC-
rAd5 boost administered at week 24 [4]. The DNA placebo was phosphate-buffered saline and
the rAd5-HIV placebo was vaccine diluent only [2–4]. The Phase 1–2 trials evaluated the same
vaccines as HVTN505. Each individual protocol was approved by institutional review boards
at all participating sites. All study participants provided written informed consent.
Meta-analysis endpoint and cohorts
The study endpoint was HIV-1 infection diagnosed during study follow-up. We predefined
two co-primary analysis cohorts for assessing the vaccine effect on HIV-1 acquisition. The
modified-intention-to-treat (MITT) cohort included all randomly assigned participants HIV-1
uninfected at study entry, who received at least the first vaccine/placebo, and the Ad5 cohort
included MITT participants who received at least one dose of rAd5-HIV vaccine or rAd5-pla-
cebo. Post-randomization selection bias could possibly exist in the Ad5 cohort but not in the
MITT cohort. The study included follow-up data through July 9, 2014.
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Statistical analysis
All reported meta-analyses were adjusted for baseline factors that could potentially confound
the vaccine effect on HIV-1 infection, especially during the post-unblinding period. The fol-
lowing baseline factors were considered: region (North America + Australia vs. Other), age,
sex, HSV-2 serostatus, race (White vs. Other), baseline Ad5 sero-positivity (Ad5-positive vs.
Table 1. Key Features of Individual Studies Included in the Meta-analysis.
Step [2] Phambili [3, 9] HVTN505 [4] IAVI001 [5] RV172 [6] HVTN204 [7]
Vaccine regimen rAd5 (week 0), rAd5 (Week 4), rAd5 (week
26)
DNA (Week 0), DNA (Week 4), DNA (Week 8), rAd5 (Week 24)
Vaccine
products
The MRKAd5 HIV-1 gag/pol/nef vaccine
consists of a 1:1:1 mixture of three separate
replication-defective Ad5 vectors, one each
expressing the gag gene from the HIV-1
strain CAM-1, the pol gene from HIV-1 strain
IIIB, and the nef gene from HIV-1 strain
JR-FL.
The DNA-HIV vaccine (VRC-HIVDNA-016-00-VP) consists of six DNA plasmid in
equal concentrations that encode Gag from the clade B HIV-1 strain HXB2, Pol from
the clade B HIV-1 strain NL4-3, and Nef from the clade B strain NY5/BRU, and HIV-1
Env glycoproteins from clade A (strain 92rw020), clade B (strain HXB2/BaL), and
clade C (strain 97ZA012). The rAd5-HIV vaccine (VRC-HIVADV014-00-VP) consists
of four rAd5 vectors in 3:1:1 ratio that encode the HIV-1 Gag-Pol polyprotein from
clade B (strains HXB2-NL4-3) and HIV-1 Env glycoproteins from clades A, B and C
matching the DNA Env components.




Four mg of VRC-DNA, 10^10 or 10^11
particle unit of VRC-Ad5
Same as
HVTN505
Placebo product Vaccine diluent with no Ad5 vector Sterile phosphate buffered saline as DNA placebo; vaccine diluent with no Ad5 vector
as Ad5 placebo
Delivery method Intramuscular injection of Ad5/placebo using
a needle and syringe
Intramuscular injection of DNA/placebo using Bioinjector 2000 Needle-Free Injection
System; intramuscular injection of Ad5/placebo using a needle and syringe
Study population High-risk, HIV-1
uninfected men who















sex with men aged
18–50 years




































































3000 801 2530 79 281 466
Vaccine 1494 400 1264 58 158 233
Placebo 1506 401 1266 21 123 233
Number of MITT
subjects
2970 800 2496 79 281 466
Vaccine 1478 400 1251 58 158 233
Placebo 1492 400 1245 21 123 233
doi:10.1371/journal.pone.0136626.t001
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Ad5-negative), self-reported circumcision status (circumcised vs. uncircumcised), and behav-
ioral risk score. The behavioral risk score was developed to summarize the level of risk behav-
iors for men and women. It takes a value from 0 to 7 for men and from 0 to 6 for women. The
risk score is defined as the number of high risk behaviors a subject self-reported during the 3–6
months prior to enrollment: for men 1) number of male partners>2, 2) use of any recreational
or injected drug, 3) unprotected insertive anal sex, 4) unprotected receptive anal sex, 5) unpro-
tected vaginal sex, 6) exchange sex for money, goods or services, 7) other sexually transmitted
infections (STIs); and for women: 1) number of male partners>2, 2) use of any recreational or
injected drug, 3) unprotected anal sex, 4) unprotected vaginal sex, 5) exchange sex, and 6)
other STIs.
We measured the vaccine effect as one minus the hazard ratio (HR) of infection (vaccine:
placebo) using multivariable Cox regression models stratified by study. To reduce bias due to
inclusion of post-unblinding data, the Cox models adjusted for the aforementioned potential
baseline confounding variables that best predicted infection based on all-subsets model selec-
tion and the exact Akaike’s information criterion (AIC). Grambsch and Therneau’s test [12]
was applied to assess whether the adjusted HR was constant over time. For the co-primary
analyses, the time-to-event variable was defined as the time from enrollment/initial vaccination
(MITT cohort) or the first rAd5-HIV vaccination (Ad5 cohort) to the estimated time of HIV-1
infection. The estimated infection time, for the Phase 2b studies, was the midpoint between the
last HIV-1 seronegative visit date and the first evidence of HIV-1 infection date based on both
HIV-1 antibody and nucleic acid blood testing, and for the Phase 1–2 studies, was the date of
HIV-1 diagnosis confirmed by ELISA, Western blot and RT-PCR. Participants who never
showed any evidence of HIV-1 infection were right censored on the date of last HIV-1 test. For
secondary analyses that restricted to data before unblinding or in the first 18 months following
vaccination, we censored the follow-up time at the date of study unblinding or 18 months. We
generated group-specific Kaplan-Meier (KM) curves, group difference of the cumulative prob-
ability of HIV-1 infection, and estimated non-parametric instantaneous HRs over time with
95% simultaneous confidence intervals [13].
We used Wald interaction tests based on Cox models to assess whether the vaccine effect
differed by study, vaccine regimen, baseline covariates (sex, Ad5 serostatus, circumcision sta-
tus), and time-varying covariates: time-period (follow-up time (FU) before or after 18 months
since enrollment, i.e., FU18 months or FU>18 months) and number of rAd5-HIV vaccina-
tions received (1, 2 or 3). Before looking into differences within a specific subset of studies or
examining the effects of a specific vaccine regimen, we first conducted overall interaction tests
to assess whether the vaccine effect differed across all six studies or all three efficacy trials, fol-
lowed by interaction tests to assess whether the vaccine effect differed between the two vaccine
regimens. Holm-Bonferroni family-wise-error-rate (FWER)-adjusted p-values and false-dis-
covery-rate (FDR)-adjusted q-values were calculated to reflect the potential effect of multiple
testing on type I errors. All reported p values were two-sided.
To investigate the power of this study in examining whether the two vaccine regimens were
similar in terms of their effect on HIV-1 infection as compared to placebo recipient, we calcu-
lated the power for comparing different true HRs between Step+Phambili and HVTN505. The
purpose of such power calculations was not to justify statistically non-significant results in a
single study, but rather to provide an understanding of the capability of the meta-analysis in
assessing whether several experiments (i.e., Step+Phambili vs. HVTN505) were similar [14].
The power calculations were based on the MITT cohort. Briefly, we fixed the total sample size,
proportion of subjects randomly allocated to vaccine and placebo, and the number of HIV-1
infections in the placebo groups of HVTN505 and Step+Phambili. Specifically, for HVTN505,
we fixed the sample size of 2496, with 1251 and 1245 MITT participants in the vaccine and
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placebo groups, respectively; we also fixed the number of HIV-1 infections in the placebo
group to be 61. For Step+Phambili, we fixed the overall sample size of3770, with 1878 and 1892
MITT participants in the vaccine and placebo groups, respectively; we also fixed the number of
HIV-1 infections in the placebo group to be 118. We studied a range of true HRs based on the
95% CI of the estimated HRs from Step+Phambili and HVTN505. Specifically, we chose the
true HR of Step+Phambili to vary between 1.11 and 1.78, and the true HR for HVTN505 to
vary between 0.47 and 1.26. For each pair of assumed true HRs, we computed the power for
testing the equality in HRs between Step+Phambi and HVTN505 based on a Wald test statistic,
assuming asymptotic normality of the difference in estimated log(HR) between the two groups;
variance of the estimated log(HR) was computed using formula (10) in [15]. A 0.05-alpha level
was used in the power calculations.
Because potential post-unblinding bias in the analysis could occur due to differential drop-
out, HIV-1 risk behavior or ascertainment of HIV-1 infection between vaccine and placebo
recipients, pre-specified simulation-based sensitivity analyses were used to assess the impact of
early unblinding in Step and Phambili. Simulations were also conducted to assess the impact of
early stopping in HVTN505 on the reported HR estimates (Methods in S1 Supporting Infor-
mation). Statistical analyses were performed with R version 2.15.1 [16]. An R function for gen-
erating the forest plots presented in this paper is included in the Supplement (Methods in S1
Supporting Information).
Results
We screened 173 articles for eligibility and identified 19 potentially relevant candidate HIV-1
vaccine studies for further review. Among the 19 studies, five evaluated DNA only [17–19] or
rAd5 only [20, 21] vaccine regimens that are different from the ones evaluated in the efficacy
trials; seven [22–28] evaluated the same vaccine regimens as the efficacy trials, but there were
resource constraints in extracting the individual-level data from those trials. Given only a mar-
ginal number of HIV infections would be added to the total HIV infections beyond the three
efficacy trials (< 6%), those 12 studies were excluded from the IPD meta-analysis. After also
excluding one duplicate study [2], up-to-date participant-level data, some of which have not
been previously published, from a total of six randomized, placebo-controlled trials of
Ad5-vectored HIV-1 vaccines were included for the final meta-analysis (Fig 2). Table 2 pro-
vides key data summary of the six studies. All MITT participants in Step (n = 2970) and Pham-
bili (n = 800) received at least one dose of rAd5-HIV vaccine or rAd5-placebo, whereas 82.8%
of MITT participants in HVTN505 (n = 2496), 92.4% in IAVI001 (n = 79), 92.2% in RV172
(n = 281) and 89.1% in HVTN204 (n = 466) received a dose of rAd5-HIV vaccine or rAd5-pla-
cebo. The annual loss to follow-up incidence pooled over the vaccine and placebo groups was
10.2% in Step, 8.2% in Phambili and 10.8% in HVTN505. Table A in S1 Supporting Informa-
tion shows the included information in the meta-analysis as compared to prior publications of
the individual trials. Figs A and B in S1 Supporting Information show the covariate-unadjusted
cumulative incidences of HIV-1 infection by treatment arm for the individual Phase 2b studies
and Triad studies.
The pooled MITT cohort included 6266 participants (n = 3129 vaccine; n = 3137 placebo)
from the three Phase 2b studies and 826 participants (n = 449 vaccine; n = 377 placebo) from
the three Phase 1–2 studies. In the MITT cohort, 76.2% and 54.7% of the Phase 2b and Phase
1–2 study participants were men, respectively. Within each sex, baseline characteristics were
balanced between the vaccine and placebo arms (Table B in S1 Supporting Information).
The pooled Ad5 cohort included 5824 participants (n = 2900 vaccine; n = 2924 placebo)
from the three Phase 2b studies and 747 participants (n = 402 vaccine; n = 345 placebo) from
Meta-Analysis of rAd5-Vector HIV-1 Vaccine Trials
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the three Phase 1–2 studies, with balanced baseline characteristic between the vaccine and pla-
cebo arms. For simplicity, we report the remaining meta-analysis results excluding the Phase
Fig 2. Study Flow Diagram.
doi:10.1371/journal.pone.0136626.g002
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Table 2. Key Data Summary of Individual Studies Included in the Meta-analysis.
Step[2] Phambili
[3, 9]
HVTN505 [4] IAVI001 [5] RV172 [6] HVTN204
[7]
Number of MITT subjects 2970 800 2496 79 281 466
Vaccine 1478 400 1251 58 158 233
Placebo 1492 400 1245 21 123 233
Percent of subjects received
0 Ad5/Placebo vaccinations 0% 0% 17.2% 8% 7% 10%
1 Ad5/Placebo vaccinations 3.0% 27.0% 82.8% 92.4% 92.2% 89.1%
2 Ad5/Placebo vaccinations 6.8% 66.1% Not applicable
(NA)
NA NA NA
3 Ad5/Placebo vaccinations 90.1% 6.9% NA NA NA NA
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1–2 studies, since over 91% of the HIV-1 infections occurred in the Phase 2b studies and both
the overall and subgroup HR estimates were very similar when the Phase 1–2 studies were
included (Fig C in S1 Supporting Information).
Overall vaccine effect in Step, Phambili, and HVTN505
The covariate-unadjusted cumulative incidences of HIV-1 infection in the MITT and Ad5
cohorts based on the phase 2b studies are plotted in Fig 3A and 3B. In the MITT cohort, 403
(n = 224 vaccine; n = 179 placebo) of 6266 participants acquired HIV-1, with a non-signifi-
cantly higher incidence in vaccine recipients (HR 1.21, 95% CI 0.99–1.48, P = 0.06). In the Ad5
cohort, 372 (n = 205 vaccine; n = 167 placebo) of 5824 participants acquired HIV-1 (HR 1.19,
95% CI 0.97–1.47, P = 0.09). The overall interaction tests indicated that the HRs significantly
differed between the three phase 2b studies in the MITT and Ad5 cohorts (P = 0.05 and 0.01,
respectively), possibly due to the difference between the two vaccine regimens. Despite the lim-
ited power to detect HR differences (Fig D in S1 Supporting Information), interaction tests
indicated that the HRs significantly differed by vaccine regimen in each of the MITT and Ad5
cohorts (P = 0.03 and 0.008, respectively (Fig 4A and 4B). Specifically, when we analyzed each
vaccine regimen, the estimated HR for DNA/rAd5 in HVTN505 was 0.88 (95% CI 0.61–1.26,
P = 0.48) in the MITT cohort and 0.73 (95% CI 0.47–1.12, P = 0.15) in the Ad5 cohort com-
pared to 1.41 (95% CI 1.11–1.78, P = 0.005) in both cohorts for MRKAd5 in Step and Phambili
combined, suggesting differences in the effect of the two vaccine regimens or in the study
populations.
In studying the overall HR in different time periods pooling over the three efficacy trials, the
overall HRs were almost identical by period of follow up (FU18 months vs. FU> 18 months)
(interaction P> 0.90) (Fig 4), and the estimated HR over time in daily increments was fairly
constant throughout follow-up (Fig E in S1 Supporting Information). An additional analysis
showed similar HRs across subgroups who received one, two, or three rAd5-HIV vaccinations
(Table C in S1 Supporting Information).
Step and Phambili pooled
Additional analyses concerning the issue of unblinding and subgroups were then conducted in
Step and Phambili combined. HVTN505 was excluded based on several considerations. First, Step
and Phambili tested the sameMRKAd5 vaccine whereas HVTN505 tested a different vaccine.
Second, the HRs differed significantly between the two vaccine regimens as shown above. Third,
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infections diagnosed after 18 months of follow-up. Lastly, Step and Phambili included Ad5-posi-
tive participants, uncircumcised men, and women, groups that were ineligible for HVTN505.
When restricting the analysis of Step and Phambili to follow-up time before unblinding
where balance in HIV-1 risk factors between the vaccine and placebo groups is most assured,
Fig 3. Kaplan-Meier Curves and Their Difference (Vaccine vs Placebo) of Cumulative Incidence of HIV-1 Infection. These incidence estimates were
not adjusted for covariates. Panel A is for the MITT cohort and Panel B is for the Ad5 cohort based on Step, Phambili and HVTN505 combined using all
follow-up time; Panel C is for the Ad5 Cohort based on HVTN505 alone using follow-up time before unblinding, and Panel D is based on Step and Phambili
combined using follow-up time before unblinding. The MITT cohort included all randomly assigned participants HIV-1 uninfected at study entry, who received
at least one dose of vaccine or placebo; the Ad5 cohort included MITT participants who received at least one dose of rAd5-HIV vaccine or rAd5-placebo.
doi:10.1371/journal.pone.0136626.g003
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114 (n = 65 vaccine; n = 49 placebo) of 3770 MITT participants acquired HIV-1, with a non-
significantly higher incidence in MRKAd5 vaccine recipients (HR 1.30, 95% CI 0.89–1.14,
P = 0.18) (Figs 3D and 5). Additional sensitivity analyses explored the impact of potential bias
in the post-unblinding period (Methods, Table D and Fig F in S1 Supporting Information).
Comparing Step and Phambili, there was no strong evidence of a differential vaccine effect
when including all follow-up, restricting to FU18 months, or restricting to FU> 18 months
(Fig G in S1 Supporting Information). Similar HRs were also observed among subgroups
defined by sex, baseline Ad5 serostatus or baseline circumcision status when evaluated over
the entire duration of follow-up (all interaction P>0.30) (Fig H(A) in S1 Supporting Informa-
tion). Of note, when restricting the analysis to circumcised and Ad5-seronegative men, the
study population participating in HVTN505, the estimated HR was 0.97 (95% CI 0.58–1.63,
P = 0.91) in Step and Phambili combined (Fig C and Fig I in S1 Supporting Information), sup-
porting that neither vaccine regimen increased HIV-1 risk in this subgroup.
We next analyzed the vaccine effect by follow-up time within each participant subgroup
(Figs H, J, and K in S1 Supporting Information). Statistical tests of interaction suggested a dif-
ferential vaccine effect by duration of follow-up and baseline circumcision status (3-way inter-
action P = 0.002). Uncircumcised men had a vaccine-increased risk of HIV-1 infection before
18 months of enrollment (HR 2.90, 95% CI 1.49–5.65, P = 0.002), whereas circumcised men
had a vaccine-increased risk after 18 months (HR 2.08, 95% CI 1.17–3.68, P = 0.01). Similarly,
the vaccine-increased risk varied by duration of follow-up and baseline Ad5 serostatus (3-way
interaction P = 0.004). Ad5-negative participants had a significant vaccine-increased risk only
after 18 months (HR 1.92, 95% CI 1.07–3.46, P = 0.03); the HRs for this group differed signifi-
cantly before and after 18 months (interaction P = 0.01). Ad5-positive participants had an
early increased risk (HR 1.92, 95% CI 1.25–2.93, P = 0.003); however, the HRs for these partici-
pants did not significantly differ by follow-up time period. Of the 24 interaction tests con-
ducted, one had an FWER-adjusted p-value< 0.05 and 11 had FDR-adjusted q-values< 0.20,
supporting that several of the differential vaccine effect results are likely to be real (Table 3).
Discussion
This meta-analysis of six randomized, double-blind, placebo-controlled clinical studies and
their long-term follow-up in 7092 participants is the first of its kind to systematically evaluate
the effect of rAd5-vectored HIV-1 vaccines on susceptibility to HIV-1 acquisition. Based on
rigorous statistical analysis of pooled individual participant-level data, we did not observe sta-
tistically significant evidence of increased risk of HIV-1 infection among vaccine recipients
when all study participants and follow-up time were considered. We observed that vaccine-
associated risk of HIV-1 infection significantly differed by vaccine regimen and/or study
population: there was evidence of increased risk for Step and Phambili that tested the
MRKAd5 vaccine in both men and women, but no evidence of vaccine-increased risk when the
VRC-DNA/rAd5 vaccine was analyzed by itself (using data from circumcised Ad5-negative
men in HVTN505, and men and women in the Triad studies). When restricting to follow-up
while the studies were blinded, the evidence for increased risk was not statistically significant
for all studies combined or separately for either vaccine regimen. When subgroups were exam-
ined separately over early and late follow-up, nominally statistically significant evidence was
Fig 4. Estimated Covariate-Adjusted HRs of HIV-1 Infection (Vaccine vs Placebo) Based on Step, Phambili and HVTN505 Combined. Panel A is for
the MITT Cohort, Panel B is for the Ad5 cohort, and Panel C is for circumcised Ad5-negative men in the Ad5 Cohort. The MITT cohort included all randomly
assigned participants HIV-1 uninfected at study entry, who received at least one dose of vaccine or placebo; the Ad5 cohort included MITT participants who
received at least one dose of rAd5-HIV vaccine or rAd5-placebo. Red lines are 95% confidence intervals indicating HRs significantly different from 1.0; blue
lines are 95% confidence intervals indicating HRs not significantly different from 1.0. Shaded rows indicate significantly different HRs within subgroups.
doi:10.1371/journal.pone.0136626.g004
Meta-Analysis of rAd5-Vector HIV-1 Vaccine Trials
PLOS ONE | DOI:10.1371/journal.pone.0136626 September 2, 2015 13 / 19
observed for early increased risk among uncircumcised men, Ad5-positive participants and
Ad5-positive men, and for late increased-risk among circumcised men, Ad5-negative partici-
pants and Ad5-negative men.
By aggregating data, meta-analysis provides statistical power to discover signals that indi-
vidual studies were under-powered to assess. Our meta-analysis demonstrated a significantly
increased risk of HIV-1 acquisition among MRKAd5 vaccine recipients who entered the trials
with evidence of past Ad5 infection; this effect appeared not to mitigate after long term follow-
up. In addition, among MRKAd5 vaccine recipients without evidence of past Ad5 infection or
who were circumcised men, significantly higher risk was seen during long term follow-up.
These observations were not previously reported in the individual studies. It is uncertain
Fig 5. Estimated HRs in the MITT Cohort (Panel A) and Ad5 Cohort (Panel B) Using Follow-up Time before Unblinding Based on Step, Phambili and
HVTN505. The MITT cohort included all randomly assigned participants HIV uninfected at study entry, who received at least one dose of vaccine or placebo;
the Ad5 cohort included MITT participants who received at least one dose of rAd5-HIV vaccine or rAd5-placebo. Blue lines are 95% confidence intervals
indicating HRs not significantly different from 1.0.
doi:10.1371/journal.pone.0136626.g005
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whether these observations were confounded by potential imbalances in HIV exposure
between the vaccine and placebo groups in the late time period due to unblinding, although the
likelihood of such confounding reversing the inference of increased risk appeared to be low
based on our sensitivity analyses. Previous studies in Step participants showed that pre-existing
Ad immunity could affect the magnitude and nature of vaccine-induced immune responses
[29, 30]. However, whether Ad-specific or other vaccine-induced immune responses are related
to differences in risk of HIV-1 acquisition after vaccination is unclear.
By aggregating data, meta-analysis also enables answering questions across study products
and/or study populations that cannot be feasibly addressed with individual studies. Our meta-
analysis showed that vaccine-associated risk of HIV-1 infection differed significantly between
the MRKAd5 and DNA/rAd5 vaccine regimens when including all study participants and
all follow-up time. When restricting to circumcised Ad5-negative men, the study population
that provided the majority of infection data for DNA/rAd5, the vaccine effect on HIV-1 infec-
tion did not seem to differ between the two vaccine regimens, and there was no evidence of
increased risk for either regimen. When restricting to follow-up while the studies were blinded,
the vaccine effect did not seem to differ, either. Although the lack of evidence in both sub-
groups could be due to the limited statistical power to detect vaccine effect differences with a
Table 3. Unadjusted and Multiplicity-Adjusted P-values from Interaction Tests of Differential Vaccine Effect by Follow-up Time Period and Sub-
group Based on Step and Phambili. Holm-Bonferroni family-wise-error-rate (FWER)-adjusted p-values and false-discovery-rate (FDR)-adjusted q-values
are reported in the last two columns.







Study (Step vs Phambili) 0.21 1.0 0.37
Gender (Male vs Female) 0.62 1.0 0.79
Ad5 serostatus (positive vs negative) 0.24 1.0 0.39
Ad5 serostatus in men (positive vs
negative)
0.37 1.0 0.55
Circumcision status (yes vs no) 0.54 1.0 0.77
FU  18 months
Study (Step vs Phambili) 0.92 1.0 0.96
Gender (Male vs Female) 0.84 1.0 0.92
Ad5 serostatus (positive vs negative) 0.004 0.09 0.03
Ad5 serostatus in men (positive vs
negative)
0.002 0.05 0.03
Circumcision status (yes vs no) 0.01 0.21 0.05
FU > 18 months
Study (Step vs Phambili) 0.06 0.96 0.15
Gender (Male vs Female) 0.61 1.0 0.79
Ad5 serostatus (positive vs negative) 0.21 1.0 0.37
Ad5 serostatus in men (positive vs
negative)
0.05 0.83 0.13
Circumcision status (yes vs no) 0.08 1.0 0.18
FU  18 months vs FU > 18
months
All participants 0.70 1.0 0.80
Female 0.96 1.0 0.96
Male 0.68 1.0 0.80
Ad5-negative 0.01 0.21 0.05
Ad5-positive 0.16 1.0 0.32
Ad5-negative men 0.003 0.07 0.03
Ad5-positive men 0.05 0.83 0.13
Circumcised men 0.02 0.40 0.08
Uncircumcised men 0.04 0.77 0.13
doi:10.1371/journal.pone.0136626.t003
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smaller number of infections, the latter analyses circumvented the issue of potential post-
unblinding confounding by measured or unmeasured factors associated with HIV-1 infection
risk. These findings suggest that differences in HIV antigen designs could have played a role in
the different vaccine effects of MARKAd5 and DNA/rAd5; however, it is prudent to address
such a hypothesis in the appropriate study populations and/or follow-up timeframe.
Because none of the trials used an empty rAd5 vector as a control arm, this meta-analysis
cannot parse out if the vaccine-associated increased risk was due to the rAd5 vector or the
HIV-1 vaccine inserts. A non-human primate challenge trial of a rAd5-vectored SIV vaccine
mimicking the MRKAd5 vaccine addressed the vector versus insert question by using a control
group of empty rAd5 vector immunized animals [31]. Although this trial recapitulated the
result in Step of vaccine-increased risk, implicating the SIV vaccine inserts as the cause, it is
unclear whether this result would apply to HIV-1 vaccines. We hypothesize that the HIV anti-
gen design and the HIV-specific immune response patterns are more likely to influence suscep-
tibility to HIV than the transient and non-specific immune stimulation of a vaccine vector.
This meta-analysis has several limitations. First, the selected trials tested two different
rAd5-vectored vaccine regimens with different biological properties in different geographic
regions and study populations. Therefore, the ability to interpret the results assumes that it is
meaningful to combine data across the multiple interventions and settings that were included.
Second, this study, like most meta-analyses, was not prospectively planned. Therefore, findings
from this study should not be regarded as additional evidence from independent experiments,
but rather integrated information across existing studies. Third, this study provided limited
power for tests of different vaccine effects due to small numbers of infections in some sub-
groups, limited long-term follow-up prior to unblinding, and limited long-term follow-up in
HVTN505. Fourth, unblinding of trial participants may have introduced bias in the analysis.
Differential dropout, risk behavior and/or ascertainment of HIV-1 infection between treatment
groups could have occurred after unblinding. To reduce such bias, all analyses controlled for
baseline measured factors potentially prognostic for HIV-1 whose distributions could differ
between treatment groups after unblinding. Future analysis may be conducted to provide
causal vaccine effect estimates adjusting for prognostic factors (e.g. risk behavior) over time.
The sensitivity analyses presented in the Supplement quantify the degree of such bias due to
both measured and unmeasured confounding that could lead to reversing a conclusion of vac-
cine-increased risk. Lastly, early stopping of HVTN505 may cause the estimate of overall vac-
cine effect to be biased, although a bias-corrected analysis of HVTN505 showed only a small
influence of early stopping (Methods and Fig L in S1 Supporting Information).
This study provides evidence for increased risk associated with the MRKAd5 vaccine overall
and in subgroups except the circumcised and Ad5-negative men. While this meta-analysis
does not provide a reliable basis for predicting whether rAd5-vectored vaccines for other path-
ogens or other rAd-vectored vaccines for HIV-1 would increase susceptibility to infection in
HIV-1 at-risk populations, for large efficacy trials of such vaccines it provides a rationale for
adding monitoring plans enabling detection of such increased susceptibility. Further research
is needed to understand which attributes of the MRKAd5 vaccine regimen should be avoided
in future HIV-1 vaccine design.
Supporting Information
S1 Supporting Information. Literature Search; R Function for Generating Forest Plots;
Sensitivity Analysis of the Impact of Early Unblinding on Hazard Ratio (HR) Estimates;
Analysis of Bias from Early Stopping in HVTN505 (Methods). Comparisons of Follow-up
Time and Number of HIV-1 Infections between the Meta-analysis and Prior Publications of
Meta-Analysis of rAd5-Vector HIV-1 Vaccine Trials
PLOS ONE | DOI:10.1371/journal.pone.0136626 September 2, 2015 16 / 19
Individual Trials (Table A). Participant Baseline Characteristics (Table B). Estimates of Time-
dependent Ad5-dose Response Based on Step and Phambili, with and without Including
HVTN505 in the Ad5 Cohort (Table C). Sensitivity Analysis Example Scenario Based on Step
and Phambili (Table D). Kaplan-Meier Curves and Their Difference of Cumulative Incidence
of HIV-1 Infection for Individual Studies: Step, Phambili, HVTN505 and the Triad studies in
the MITT Cohort (Fig A). Kaplan-Meier Curves and Their Difference of Cumulative Incidence
of HIV-1 Infection for Individual Studies: Step, Phambili, HVTN505 and the Triad studies in
the Ad5 Cohort (Fig B). Estimated HRs in the MITT Cohort (Panel A) and Ad5 Cohort (Panel
B) Based on All Six Studies (Fig C). Power Calculations for Vaccine Effect Comparisons
between HVTN505 vs. Step and Phambili Combined Based on Sample Sizes in the MITT
Cohort (Panel A) and the Ad5 Cohort (Panel B) (Fig D). Nonparametric Instantaneous HR of
Infection in the MITT Cohort (Panel A) and the Ad5 Cohort (Panel B) Based on Step, Pham-
bili and HVTN505 (Fig E). Sensitivity Analysis to Assess the Impact of Post-unblinding Bias
Based on Step and Phambili Combined (Fig F). Estimated HRs by Study and Follow-up Time
Period Based on Step and Phambili (Fig G). Estimated HRs in Subgroups Using Follow-up
Time Overall (Panel A), before 18 Months (Panel B) and after 18 Months (Panel C) Based on
Step and Phambili (Fig H). Estimated HRs in the MITT Cohort (Panel A) and the Ad5 Cohort
(Panel B) among Circumcised Ad5-negative Men Based on Step, Phambili and HVTN505
(Fig I). Estimated HRs by Follow-up Time Period in Subgroups Defined by Baseline Circumci-
sion Status and Ad5 Serostatus Based on Step and Phambili (Fig J). Summary of Estimated
HRs and Interaction Test P-values by Follow-up Time Period and by Subgroups Defined by
Baseline Circumcision Status and Ad5 Serostatus Based on Step and Phambili (Fig K). Bias-
corrected Relative Risk Accounting for Early Stopping in HVTN505 (Fig L).
(DOCX)
S2 Supporting Information. PRISMA Checklist.
(DOCX)
Acknowledgments
We thank Carl Verlinde (International AIDS Vaccine Initiative), Kelley Loughran (EMMES),
Alicia Sato (Fred Hutchinson Cancer Research Center) for facilitating the acquisition of
IAVI001 data; Mark Milazzo (US Military HIV Research Program), for the acquisition of
RV172 data; Julie Stofel (Fred Hutchinson Cancer Research Center) for the acquisition of
HVTN204 data; Doug Grove (Fred Hutchinson Cancer Research Center) for the acquisition of
HVTN505 data; Margo Rogers (Fred Hutchinson Cancer Research Center) and Mindy Miner
(Fred Hutchinson Cancer Research Center) for providing administrative and editorial assis-
tance. No compensation was received by any individual for assistance with this study.
Author Contributions
Conceived and designed the experiments: Yunda Huang DF MN DVM LC JGKMR SMH
GEG SPB PBG. Performed the experiments: Yunda Huang DF LZ MN Ying Huang PBG. Ana-
lyzed the data: Yunda Huang DF LZ MN Ying Huang PBG. Wrote the paper: Yunda Huang
DF MN LZ Ying Huang DVM ZM BMHJ MCK GCMLR PEF ADMJM LC JRM BSGMES
JGKMR SMH GEG SPB PBG. Acquisition of data: Yunda Huang DF BMMLR PBG.
Meta-Analysis of rAd5-Vector HIV-1 Vaccine Trials
PLOS ONE | DOI:10.1371/journal.pone.0136626 September 2, 2015 17 / 19
References
1. Choi Y, Chang J. Viral vectors for vaccine applications. Clinical and experimental vaccine research.
2013; 2(2):97–105. doi: 10.7774/cevr.2013.2.2.97 PMID: 23858400
2. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, et al. Efficacy assessment of a
cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-con-
trolled, test-of-concept trial. Lancet. 2008; 372(9653):1881–93. doi: 10.1016/S0140-6736(08)61591-3
PMID: 19012954
3. Gray GE, Allen M, Moodie Z, Churchyard G, Bekker LG, Nchabeleng M, et al. Safety and efficacy of the
HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, rando-
mised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis. 2011; 11(7):507–15. doi:
10.1016/S1473-3099(11)70098-6 PMID: 21570355
4. Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, Grove D, et al. Efficacy trial of a
DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med. 2013; 369(22):2083–92. doi: 10.1056/
NEJMoa1310566 PMID: 24099601
5. JaokoW, Karita E, Kayitenkore K, Omosa-Manyonyi G, Allen S, Than S, et al. Safety and immunoge-
nicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-
1 DNA vaccine in Africa. PLoS One. 2010; 5(9):e12873. doi: 10.1371/journal.pone.0012873 PMID:
20877623
6. Kibuuka H, Kimutai R, Maboko L, Sawe F, Schunk MS, Kroidl A, et al. A phase 1/2 study of a multiclade
HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected
East Africans (RV 172). J Infect Dis. 2010; 201(4):600–7. doi: 10.1086/650299 PMID: 20078213
7. Churchyard GJ, Morgan C, Adams E, Hural J, Graham BS, Moodie Z, et al. A phase IIA randomized
clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in
healthy adults (HVTN204). PLoS One. 2011; 6(8):e21225. doi: 10.1371/journal.pone.0021225 PMID:
21857901
8. Duerr A, Huang Y, Buchbinder S, Coombs RW, Sanchez J, del Rio C, et al. Extended follow-up con-
firms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among
participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). J Infect Dis.
2012; 206(2):258–66. doi: 10.1093/infdis/jis342 PMID: 22561365
9. Gray GE, Moodie Z, Metch B, Gilbert PB, Bekker LG, Churchyard G, et al. Recombinant adenovirus
type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN
503/Phambili study. Lancet Infect Dis. 2014; 14(5):388–96. doi: 10.1016/S1473-3099(14)70020-9
PMID: 24560541
10. Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: rationale, conduct, and
reporting. Bmj. 2010; 340:c221. doi: 10.1136/bmj.c221 PMID: 20139215
11. Fisher DJ, Copas AJ, Tierney JF, Parmar MK. A critical review of methods for the assessment of
patient-level interactions in individual participant data meta-analysis of randomized trials, and guidance
for practitioners. Journal of clinical epidemiology. 2011; 64(9):949–67. doi: 10.1016/j.jclinepi.2010.11.
016 PMID: 21411280
12. Grambsch PM, Therneau TM. Proportional Hazards Tests and Diagnostics Based onWeighted Resid-
uals. Biometrika. 1994; 81(3):515–26.
13. Wu L, Gilbert PB. Flexible weighted log-rank tests optimal for detecting early and/or late survival differ-
ences. Biometrics. 2002; 58(4):997–1004. PMID: 12495155
14. Hoenig JM, Heisey DM. The abuse of power: The pervasive fallacy of power calculations for data analy-
sis. Am Stat. 2001; 55(1):19–24.
15. Williamson PR, Smith CT, Hutton JL, Marson AG. Aggregate data meta-analysis with time-to-event out-
comes. Statistics in medicine. 2002; 21(22):3337–51. PMID: 12407676
16. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical
Computing. Vienna, Austria2012.
17. Catanzaro AT, Roederer M, Koup RA, Bailer RT, EnamaME, Nason MC, et al. Phase I clinical evalua-
tion of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine. 2007; 25(20):4085–92. PMID:
17391815
18. Graham BS, Koup RA, Roederer M, Bailer RT, EnamaME, Moodie Z, et al. Phase 1 safety and immu-
nogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis. 2006; 194(12):1650–
60. PMID: 17109336
19. Tavel JA, Martin JE, Kelly GG, EnamaME, Shen JM, Gomez PL, et al. Safety and immunogenicity of a
Gag-Pol candidate HIV-1 DNA vaccine administered by a needle-free device in HIV-1-seronegative
subjects. J Acquir Immune Defic Syndr. 2007; 44(5):601–5. PMID: 17325604
Meta-Analysis of rAd5-Vector HIV-1 Vaccine Trials
PLOS ONE | DOI:10.1371/journal.pone.0136626 September 2, 2015 18 / 19
20. Nicholson O, Dicandilo F, Kublin J, Sun X, Quirk E, Miller M, et al. Safety and Immunogenicity of the
MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy Adults. AIDS Res Hum
Retroviruses. 2010.
21. Catanzaro AT, Koup RA, Roederer M, Bailer RT, EnamaME, Moodie Z, et al. Phase 1 safety and
immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective
recombinant adenovirus vector. J Infect Dis. 2006; 194(12):1638–49. PMID: 17109335
22. Priddy FH, Brown D, Kublin J, Monahan K, Wright DP, Lalezari J, et al. Safety and immunogenicity of a
replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin
Infect Dis. 2008; 46(11):1769–81. doi: 10.1086/587993 PMID: 18433307
23. Harro C, Sun X, Stek JE, Leavitt RY, Mehrotra DV, Wang F, et al. Safety and immunogenicity of the
Merck adenovirus serotype 5 (MRKAd5) and MRKAd6 human immunodeficiency virus type 1 trigene
vaccines alone and in combination in healthy adults. Clin Vaccine Immunol. 2009; 16(9):1285–92. doi:
10.1128/CVI.00144-09 PMID: 19605598
24. Harro CD, Robertson MN, Lally MA, O'Neill LD, Edupuganti S, Goepfert PA, et al. Safety and immuno-
genicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults.
AIDS Res Hum Retroviruses. 2009; 25(1):103–14. doi: 10.1089/aid.2008.0212 PMID: 19108693
25. Graham BS, Enama ME, Nason MC, Gordon IJ, Peel SA, Ledgerwood JE, et al. DNA vaccine delivered
by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses
after rAd5 boost in a randomized clinical trial. PLoS One. 2013; 8(4):e59340. doi: 10.1371/journal.
pone.0059340 PMID: 23577062
26. Peiperl L, Morgan C, Moodie Z, Li H, Russell N, Graham BS, et al. Safety and immunogenicity of a repli-
cation-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical
trial (HVTN 054). PLoS One. 2010; 5(10):e13579. doi: 10.1371/journal.pone.0013579 PMID: 21048953
27. De Rosa SC, Thomas EP, Bui J, Huang Y, deCamp A, Morgan C, et al. HIV-DNA priming alters T cell
responses to HIV-adenovirus vaccine even when responses to DNA are undetectable. J Immunol.
2011; 187(6):3391–401. doi: 10.4049/jimmunol.1101421 PMID: 21844392
28. Koblin BA, Casapia M, Morgan C, Qin L, Wang ZM, Defawe OD, et al. Safety and immunogenicity of an
HIV adenoviral vector boost after DNA plasmid vaccine prime by route of administration: A randomized
clinical trial. PLoS One. 2011; 6(9):e24517. doi: 10.1371/journal.pone.0024517 PMID: 21931737
29. McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, et al. HIV-1 vaccine-induced
immunity in the test-of-concept Step Study: A case-cohort analysis. Lancet. 2008; 372(9653):1894–
905. doi: 10.1016/S0140-6736(08)61592-5 PMID: 19012957
30. Frahm N, DeCamp AC, Friedrich DP, Carter DK, Defawe OD, Kublin JG, et al. Human adenovirus-spe-
cific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine. J Clin Invest.
2012; 122(1):359–67. doi: 10.1172/JCI60202 PMID: 22201684
31. Qureshi H, Ma ZM, Huang Y, Hodge G, Thomas MA, DiPasquale J, et al. Low-dose penile SIVmac251
exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replica-
tion-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of
a similar HIV-1 vaccine. J Virol. 2012; 86(4):2239–50. doi: 10.1128/JVI.06175-11 PMID: 22156519
Meta-Analysis of rAd5-Vector HIV-1 Vaccine Trials
PLOS ONE | DOI:10.1371/journal.pone.0136626 September 2, 2015 19 / 19
